Research programme: asthma therapy - Sirna TherapeuticsAlternative Names: Asthma therapy research programme - Sirna Therapeutics
Latest Information Update: 29 Jan 2008
At a glance
- Originator Sirna Therapeutics
- Class RNA
- Mechanism of Action Cytokine modulators; RNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
- 10 Jan 2005 Preclinical trials in Asthma in USA (Inhalation)